Endocrine Module 03Hypothalamic-Pituitary Relationships II — Growth Hormone

1 · Why GH signaling has a hypothalamus-pituitary-liver-tissue cascade

• Level 1 — Hypothalamic control:
  • GHRH (stimulates) and somatostatin (inhibits) are co-released from separate hypothalamic neurons.end03 lecture
  • They converge on the same signaling pathway (cAMP) in somatotropes, but in opposite directions.FA 3.02 Growth hormone
• Level 2 — Pituitary integration:
  • Somatotropes release GH in pulses when GHRH dominates.end03 lecture
  • Somatostatin sharpens the pulses by cutting off secretion between peaks.
• Level 3 — Hepatic IGF-1 amplification:
  • Most of GH's growth effects are mediated by IGF-1, not GH directly.FA 3.02 GH; B&B 5.01
  • IGF-1 half-life is ~36× longer than GH, creating sustained anabolic signaling.
• Level 4 — Target tissue response:
  • IGF-1 acts on bone, cartilage, muscle, and most cell types via the IGF1-R (RTK).
  • GH also has direct effects on muscle and adipose via the GH-R (JAK-STAT).

2 · GHRH and somatostatin — opposing pathways that converge

• Structure:
  • 44-AA peptide from the ventromedial and arcuate nuclei.FA 3.01 Hypothalamic-pituitary hormones
• Signal transduction:
  • Binds a Gs-coupled GPCR on somatotropes.
  • ↑ cAMP → PKA → Ca²⁺ influx → vesicle fusion → GH release.

• Structure:
  • 14- or 28-AA cyclic peptide from the periventricular nucleus.FA 3.01
• Signal transduction:
  • Binds a Gi-coupled GPCR on somatotropes.
  • ↓ cAMP → suppresses GH release.
• Clinical use:
  • Octreotide and lanreotide are somatostatin analogs used to suppress GH in acromegaly.AI Generated · see end13

3 · GH receptor & JAK-STAT — how GH induces IGF-1

• Structure:
  • GH-R is a single-pass transmembrane receptor with no intrinsic kinase activity.FA 3.14 Signaling pathways; B&B 5.06
  • GH binds → receptor dimerizes → recruits JAK2 kinases.
• Downstream signaling:
  • JAK2 autophosphorylates and phosphorylates receptor cytoplasmic tails.
  • STAT5 binds phosphorylated receptor, gets phosphorylated, dimerizes, translocates to nucleus.
  • STAT5 binds DNA → induces IGF-1 transcription.FA 3.02 Growth hormone

• Acidophilic pituitary hormones:
  • GH and prolactin — both from acidophils.
• Hematopoietic hormones:
  • EPO and TPO.
• Cytokines:
  • Most interleukins, interferons, leptin.FA 3.14 Signaling pathways

4 · IGF-1 and the somatomedin family

• IGF-1 (somatomedin C):
  • 70-AA peptide, mostly from the liver.end03 lecture
  • Stimulates mitogenic + anabolic processes + cell survival in nearly all cell types.
• IGF-1 receptor:
  • Distinct from GH receptor.
  • Receptor tyrosine kinase (RTK) — structurally related to insulin receptor.
  • Activates MAPK (growth) and PI3K-AKT (survival, metabolism) pathways.FA 3.02 Growth hormone; FA 3.14 Signaling
• Other somatomedins:
  • IGF-2 (somatomedin A) and others play roles in fetal growth.
  • IGF-1 is by far the most studied and clinically important.

5 · Carrier proteins — GHBP and IGFBP

• GHBP (GH-binding protein):
  • Binds ~50% of circulating GH.
  • Structurally, GHBP is the extracellular domain of the GH receptor.end03 lecture
  • Small GH molecule otherwise freely filtered by the kidney — binding slows this.
  • Even with GHBP, GH half-life remains only ~20 minutes — hence its pulsatile nature.
• IGFBP (IGF-binding proteins):
  • 6 subtypes (IGFBP-1 through IGFBP-6); IGFBP-3 is most common.
  • Nearly all IGF-1 circulates bound.
  • Binding greatly extends half-life to ~12 hours.end03 lecture; FA 3.02 GH
• IGFBP proteases:
  • Tissue-level proteases cleave IGFBP → free IGF-1 → activates local IGF1-R.
  • Allows targeted release despite the long-circulating bound pool.

6 · GH-PRL cross-reactivity

• Homology:
  • GH and prolactin share a common ancestor and have high sequence homology.end03 lecture
• Receptor cross-binding:
  • GH can bind the prolactin receptor with decent affinity.
  • Explains why GH-secreting adenomas can cause galactorrhea even without coexisting hyperprolactinemia.AI Generated · see end08 pituitary adenomas
• Human placental lactogen (hPL):
  • Placental hormone structurally similar to GH and PRL — GH-like effects during pregnancy.FA 3.01 Hypothalamic-pituitary hormones

1 · Direct vs. indirect effects in detail

• Physiologic logic:
  • Direct effects handle acute metabolic needs (glucose/fat).
  • Indirect effects drive chronic growth and repair.
  • The split lets GH do "short-term fuel management" AND "long-term growth" from one hormone.end03 lecture

2 · The diabetogenic effect

• Where it happens:
  • Skeletal muscle and adipose tissue.end03 lecture
• What GH does:
  • Reduces insulin sensitivity in these tissues.
  • Decreases glucose uptake and increases lipolysis.
  • Net effect: glucose is preserved for the brain; fat is burned for energy.
• Chronic overexposure:
  • Prolonged GH excess → sustained insulin resistance → clinically evident diabetes mellitus.
  • Classic feature of acromegaly.FA 3.02 GH; Bootcamp 3.04 Acromegaly

3 · Tissue-specific effects

• Via GH (direct):
  • ↑ gluconeogenesis → raises serum glucose.
  • ↑ IGF-1 production (JAK-STAT → STAT5 → IGF-1 transcription).FA 3.02 GH
• Insulin's permissive role:
  • Insulin drives GH-R expression on hepatocytes.
  • Without insulin (uncontrolled T1DM), GH → IGF-1 is blunted → growth failure in children.end03 lecture

• Direct GH effects:
  • ↑ lipolysis → ↑ free fatty acids in circulation.
  • ↓ glucose uptake (insulin resistance).
• Clinical translation:
  • GH excess → decreased body fat, increased muscle mass.
  • GH replacement therapy in GHD → reduced adiposity.Bootcamp 3.05 GHD

• Direct effects:
  • ↓ glucose uptake (insulin resistance).
  • ↑ amino acid uptake (substrate for protein synthesis).
• Indirect effects via IGF-1:
  • ↑ protein synthesis.
  • ↑ muscle mass and strength.FA 3.02 GH

• IGF-1 is the growth engine:
  • Chondrocytes of the epiphyseal plate proliferate under IGF-1.
  • Linear bone growth occurs until epiphyseal closure.FA 3.02 GH; Bootcamp 3.04
• After epiphyseal closure:
  • Linear growth stops.
  • Continued GH excess thickens bones (jaw, hands, feet) — acromegaly.

4 · Fed vs. fasted physiology

• Hormonal environment:
  • ↑ amino acids → stimulate GH.
  • ↑ glucose → insulin release.
  • Insulin permits hepatic GH → IGF-1.end03 lecture
• Net effect:
  • Anabolism and tissue growth.
  • This is why kids need balanced meals to grow.

• Hormonal environment:
  • ↓ glucose → stimulates GH release (removes inhibition).
  • ↓ insulin → blunts hepatic GH-R → less IGF-1.end03 lecture
• Net effect:
  • GH's direct anti-insulin effects dominate.
  • Glucose spared for brain; adipose broken down for fuel.

5 · Insulin's permissive role

• Key concept:
  • Insulin up-regulates GH-R expression on hepatocytes.
  • Without adequate insulin, hepatic IGF-1 production falters despite high GH.end03 lecture
• Clinical manifestation:
  • Children with poorly controlled T1DM often have growth failure despite high GH levels.
  • IGF-1 levels are the actual limiting factor.AI Generated · see end17

6 · Pregnancy and human placental lactogen (hPL)

• hPL:
  • Also called human chorionic somatomammotropin (hCS).
  • Placental hormone structurally similar to GH and PRL.end03 lecture; FA 3.01
• Physiology:
  • hPL mimics GH effects in pregnancy — diabetogenic, lipolytic.
  • Helps mobilize maternal fuel for the fetus.
  • Contributes to gestational insulin resistance and gestational diabetes.AI Generated · obstetrics
• Feedback on GH:
  • hPL suppresses maternal GH (via feedback on hypothalamus).

1 · Pulsatile secretion — what creates the pulses?

• How the pulses form:
  • Somatotropes are continuously exposed to waves of GHRH (stimulatory) and somatostatin (inhibitory).
  • When GHRH dominates, a burst of GH is released.
  • When somatostatin dominates, secretion is shut off, sharpening the trough.end03 lecture
• Frequency:
  • ~Every 4 hours across the day.
  • The largest pulse is during deep (slow-wave) sleep.
• Why pulsatility matters:
  • Prevents target-cell desensitization to GH.
  • Continuous GH exposure would blunt downstream signaling (similar principle to GnRH pulsatility).FA 3.02 GH

2 · Three feedback loops

• Mechanism:
  • GHRH (and somatostatin) neurons inhibit their own subsequent firing through local collaterals.
  • Creates pulsatile release.end03 lecture

• Mechanism:
  • GH itself feeds back on the hypothalamus.
  • Increases somatostatin release and decreases GHRH.

• Mechanism:
  • IGF-1 from the liver feeds back on BOTH hypothalamus and pituitary.
  • ↑ somatostatin; ↓ GH release directly from somatotropes.FA 3.02 GH; B&B 5.01
• Clinical relevance:
  • In GH-secreting adenomas, high IGF-1 usually fails to suppress tumor GH output (autonomous secretion).
  • Basis of the glucose suppression test (below) — normal feedback is absent.Bootcamp 3.04 Acromegaly

3 · Circadian regulation

• Timing:
  • GH peaks during stage 3/4 (slow-wave) sleep, typically around midnight.end03 lecture
• Melatonin stimulates GH:
  • Pineal melatonin release overlaps the first stage of sleep.
  • Melatonin has direct stimulatory effects on GH release.
• Clinical implications:
  • Children with sleep disorders or chronic sleep deprivation may have blunted growth.
  • GH stim testing can be done overnight when ambiguous.AI Generated · see end13

• Why:
  • Transient hypoglycemia and increased catecholamines during exercise stimulate GH release.
  • Used in GH stimulation tests.AI Generated · see end13

4 · Lifetime pattern

• Low at birth:
  • Serum GH rises rapidly after the first few months.
  • Fetal growth is primarily driven by IGF-2, not GH.end03 lecture

• High baseline:
  • Steady GH drives linear growth and organ development.
  • Poor sleep or poor nutrition at this stage stunts growth.

• Why highest:
  • Rising sex steroids (estradiol and testosterone) sensitize somatotropes and stimulate GH release.end03 lecture; FA 3.02 GH
  • Creates the "growth spurt."
• Epiphyseal closure:
  • Estrogen eventually drives epiphyseal closure → terminates linear growth.
  • After this, GH excess thickens bones and soft tissues (acromegaly) rather than lengthening.

• Plateau:
  • GH declines from pubertal peak to a lower adult baseline.
  • Role shifts from growth to tissue maintenance and metabolic regulation.

• Further decline:
  • Declining sex steroids with aging → reduced GH secretion.
  • Contributes to age-related sarcopenia and increased adiposity.end03 lecture

5 · Sex steroids as GH amplifiers at puberty

• Mechanism:
  • Estradiol and testosterone both enhance GHRH release and somatotrope sensitivity.FA 3.02 GH
• Testosterone's indirect effect:
  • Testosterone is aromatized peripherally to estradiol, which is actually the primary driver of the pubertal GH surge.
• Clinical:
  • Children with hypogonadism (Klinefelter, Turner, Kallmann) often have blunted pubertal GH surge → short adult stature unless gonadal hormones are replaced.AI Generated · repro/end05

1 · Metabolic stimuli and inhibitors

• ↓ glucose → ↑ GH:
  • Hypoglycemia is a powerful stimulator.end03 lecture
  • Clinical use: insulin tolerance test — induce hypoglycemia, check that GH rises appropriately.
• ↑ glucose → ↓ GH:
  • Hyperglycemia suppresses GH.
  • Clinical use: oral glucose tolerance test (OGTT) — give 75g glucose, check GH. Normal: GH falls. Acromegaly: GH fails to suppress.FA 3.02 GH; Bootcamp 3.04 Acromegaly

• ↓ FFA → ↑ GH:
  • Low fat availability signals fuel need.
• ↑ FFA → ↓ GH:
  • High circulating fat suppresses GH.end03 lecture

• ↑ amino acids → ↑ GH:
  • Especially arginine and leucine.end03 lecture; FA 3.02 GH
  • Arginine stimulation test is used clinically for GH reserve assessment.

2 · Nutritional state

• Fasting / caloric deprivation:
  • Low glucose + low insulin drives GH release.end03 lecture
  • GH's direct anti-insulin effects dominate → glucose-sparing, lipolysis.
• Chronic malnutrition:
  • High GH but LOW IGF-1 (because insulin is low, so hepatic GH-R is down).
  • Growth failure despite high GH.AI Generated · pediatrics / nutrition

3 · Sleep, stress, and exercise

• Deep sleep (stage 4, slow-wave):
  • Largest physiologic GH pulse.end03 lecture
  • Melatonin contributes.
• Exercise:
  • Increases GH through transient hypoglycemia and catecholamine release.end03 lecture
• Stress — the paradox:
  • Acute / physiologic cortisol → permissive, enhances GH.
  • Chronic / hypercortisolemia → suppresses GH.end03 lecture; FA 3.02 GH

4 · Hormonal amplifiers

• Estradiol (dominant) and testosterone:
  • Enhance GHRH release and somatotrope responsiveness.end03 lecture
  • Drive the pubertal GH surge.
• Peripheral aromatization:
  • Testosterone → estradiol (via aromatase).
  • Estradiol is the main driver of the pubertal growth spurt even in males.FA 3.02 GH; repro xref

• Origin:
  • Secreted by gastric oxyntic cells and hypothalamic arcuate nucleus.
• Actions:
  • Stimulates GH release.
  • Also promotes appetite ("hunger hormone").FA 3.02 GH; B&B 5.01

5 · Inhibitors in detail

• Mechanism:
  • Chronically high cortisol suppresses GHRH and somatotrope sensitivity.end03 lecture
• Clinical:
  • Cushing's syndrome → growth failure in children.
  • Chronic glucocorticoid therapy can cause GHD → short stature.AI Generated · see end21

• hPL:
  • Placental lactogen (also called human chorionic somatomammotropin).
  • Structurally similar to GH and PRL; GH-like effects.end03 lecture; FA 3.01
• Feedback:
  • hPL feedback-suppresses maternal GH (makes sense — redundancy).
  • Maternal IGF-1 rises due to hPL's GH-like activity on liver.

6 · GH stimulation and suppression testing

• Screening:
  • Serum IGF-1 (stable, 12-h half-life).FA 3.02 GH; Bootcamp 3.04
• Confirmatory — oral glucose suppression test (OGTT):
  • Give 75 g oral glucose.
  • Normal: GH suppresses to <1 ng/mL.
  • Acromegaly: GH fails to suppress (often paradoxically rises).
• Imaging:
  • MRI pituitary to localize adenoma.

• Insulin tolerance test:
  • Give IV insulin → induce hypoglycemia.
  • Normal: GH should rise (>5–10 ng/mL).
  • GHD: GH fails to rise.AI Generated · see end13
• Arginine stimulation test:
  • IV arginine should stimulate GH.
  • Safer alternative when hypoglycemia is contraindicated.
• GHRH + arginine test:
  • Combined stimulus — very sensitive.

1 · GH deficiency (pituitary dwarfism)

• Cause:
  • Decreased production of GH by the anterior pituitary.end03 lecture
  • Can be congenital (pituitary developmental disorders) or acquired (tumors, trauma, radiation, Sheehan).
• Presentation:
  • Proportionate short stature in children.
  • Reduced muscle mass, central adiposity, exercise intolerance in adults.Bootcamp 3.05 GH Deficiency

• Low IGF-1 and low GH (pulsatile).
• Failed GH rise on stimulation testing (insulin tolerance or arginine).AI Generated · see end13

• Recombinant GH (somatropin):
  • Daily subcutaneous injection.
  • Start young for best height outcomes.
  • Monitor IGF-1 levels to titrate dose.AI Generated · see end13

2 · Laron syndrome (GH insensitivity)

• Molecular defect:
  • Loss-of-function mutation in the GH receptor (or its JAK-STAT signaling machinery).end03 lecture; FA 3.02 GH
• Consequences:
  • High GH (no negative feedback from IGF-1).
  • Low IGF-1 (receptor defect blocks hepatic IGF-1 synthesis).
  • Short stature despite high GH.

• Paradoxical health benefits:
  • Laron patients have very low cancer incidence and decreased diabetes risk.
  • Low IGF-1 signaling appears protective for some diseases of aging.AI Generated · research context

• Mecasermin (recombinant IGF-1):
  • Bypasses the broken GH receptor.
  • GH itself is useless.AI Generated · see end13

3 · Gigantism

• GH excess before epiphyseal closure:
  • High GH + high IGF-1 → excessive linear bone growth.end03 lecture
• Usual cause:
  • GH-secreting pituitary adenoma in childhood.

• Very tall stature (can reach 7+ feet).
• Often disproportionate in the limbs.
• Severe cardiovascular and metabolic complications — gigantism is more severe than acromegaly despite similar biochemistry.end03 lecture

4 · Acromegaly

• GH excess after epiphyseal closure:
  • Long bones cannot lengthen, but can thicken.
  • Soft tissues and organs grow.end03 lecture
• Usual cause:
  • GH-secreting pituitary adenoma (2nd most common functional adenoma after prolactinoma).Bootcamp 3.04 Acromegaly

• "Big and thick":
  • Enlarged jaw (prognathism), hands, feet.
  • Coarse facial features, macroglossia, widely spaced teeth.
  • Thick skin, skin tags, oily skin.
• Associated complications:
  • Diabetes mellitus (insulin resistance).
  • Hypertension, cardiomyopathy, heart failure (leading cause of death).
  • Carpal tunnel syndrome (median nerve entrapment).
  • Obstructive sleep apnea (soft tissue enlargement).
  • Colon polyps and increased colorectal cancer risk.FA 3.02 GH; Bootcamp 3.04
• Mass effect from macroadenoma:
  • Bitemporal hemianopsia.
  • Headache.
  • Hypopituitarism from compression.AI Generated · see end08

5 · Pituitary adenomas — functional and non-functional

• Microadenoma:
  • <10 mm.
  • Often detected because of functional hormone secretion (hormone excess) rather than mass effect.end03 lecture; Pathoma 15.01
• Macroadenoma:
  • ≥10 mm.
  • Can cause mass effect: bitemporal hemianopsia, cranial nerve palsies, hypopituitarism.

• Prolactinoma — most common.
• GH-secreting adenoma — 2nd most common (causes gigantism/acromegaly).
• ACTH-secreting (Cushing disease).
• TSH-secreting (TSHoma, rare).
• Non-functional adenomas — present with mass effect only.Pathoma 15.01 Pituitary Gland; AI Generated · see end08

6 · Diagnostic workup for GH excess

• Step 1 — Screening:
  • Serum IGF-1 (age-adjusted).
  • Stable, long half-life; best first test.FA 3.02 GH; Bootcamp 3.04
• Step 2 — Confirmation:
  • Oral glucose suppression test (75g glucose).
  • Normal: GH <1 ng/mL. Acromegaly: fails to suppress; may paradoxically rise.
• Step 3 — Localization:
  • MRI pituitary with contrast.
  • If pituitary negative → consider ectopic GHRH source (rare, e.g., pancreatic NET).AI Generated · see end08
• Step 4 — Comorbidity screening:
  • HbA1c, BP, echocardiogram, sleep study, colonoscopy.

7 · Treatments in detail

• Transsphenoidal adenoma resection:
  • Goal: biochemical cure (normal IGF-1 + post-op GH <1 on OGTT).
  • Microadenoma cure rate >85%; macroadenoma lower.Bootcamp 3.04 Acromegaly; AI Generated · see end13

• Somatostatin analogs (octreotide, lanreotide):
  • Mimic physiological somatostatin (Gi inhibition of GH).
  • First-line medical therapy.AI Generated · see end13; Lippincott Pharm
• GH receptor antagonist (pegvisomant):
  • Pegylated GH analog that binds GH-R but doesn't trigger signaling.
  • Normalizes IGF-1 (but GH levels rise because it doesn't feedback).
  • Used when somatostatin analogs fail.
• Dopamine agonists (cabergoline, bromocriptine):
  • Less effective for acromegaly than for prolactinoma.
  • Useful if GH adenoma co-secretes prolactin.
• Radiation:
  • Reserved for refractory cases.
  • Slow onset (years).